Different concepts in first-line treatment of essential hypertension: Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy

Hypertension

Volumn 29, Issue 2, 1997, Pages 651-658

  Krönig, Bernd ^a   Pittrow, David Bernhard ^b   Kirch, Wilhelm ^c   Welzel, Dieter ^c   Weidinger, Gottfried ^b  

^a Ev Elisabeth Krankenhaus Trier gemgGmbH   (Germany)

^b Product Development   (Germany)

^c Department of Clinical Research ^*

Author keywords

clopamid; combination therapy; controlled trial; hypertension, essential; low dose; nitrendipine; reserpine

Indexed keywords

NITRENDIPINE; RESERPINE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0005816752     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.2.651     Document Type: Article

References (36)

1. Fingl E, Woodbury DM. General principles. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 4th ed. New York, NY: Macmillan Publishing Co; 1970:24-25.
2. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens. 1987; 3:278-293.
3. Dengler HJ, Lasagna L. Report of a workshop on fixed-ratio drug combinations. Eur J Clin Pharmacol. 1975;8:149-154.
4. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med. 1994;154:1430-1431.
5. MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Safety. 1995;12:85-90.
6. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension. II: results for in-patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
8. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
9. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J, for the SHEP Cooperative Research Group. Effect of atenolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP). Am J Hypertens. 1995;8:1147-1153.
10. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I: reductions in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571.
11. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA. 1988;259:2113-2122.
12. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH, Khatri I, Schnaper H, Thomas JR, Henderson WG, Fye C. Treatment of hypertension in the elderly, I: blood pressure and clinical changes: results of a Department of Veterans Affairs Cooperative Study. Hypertension. 1990;15:348-360.
13. McMahon FG, Brobyn R, Kann J, Levy B, Margolis R, Reeves R. A double-blind comparative study of nitrendipine and propranolol in the treatment of hypertension. J Cardiovasc Pharmacol. 1987; 9(suppl 4):228-231.
14. Lassen E, Frimodt-Møller J, Ahlstrøm F, Bøgeskov-Jensen I, Nielsen MR, Wickers-Nielsen N, Winkel OP. Antihypertensive efficacy and safety of felodipine compared with nitrendipine in mild to moderate hypertension. Curr Ther Res. 1993;53:654-664.
15. Jamieson MJ, Webster J, Witte K, Huggins MM, MacDonald TM, de Beaux A, Petrie JC. An evaluation of the A&D UA-751 semi-automated cuff-oscillometric sphygmomanometer. J Hypertens. 1990; 8:377-381.
16. Association for the Advancement of Medical Instrumentation. American National Standard: Electronic or Automated Sphygmomanometers. Arlington, Va: Association for the Advancement of Medical Instrumentation, 1987.
17. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens. 1992;5:207-209.
18. Reid JL. First-line and combination treatment for hypertension. Am J Med. 1989;86(suppl 4A):2-5.
19. Brunner HR, Ménard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M. Treating the individual hypertensive patient: considerations of dose, sequential monotherapy and drug combinations. J Hypertens. 1990;8:3-11. Editorial review.
20. Shenfield GM. Fixed combination drug therapy. Drugs. 1982;23: 462-480.
21. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP, Carr AA. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J. 1995;130:359-366.
22. Henry D. Comparing treatments. BMJ. 1995;310:1279.
23. Bruce NG, Shaper AG, Walker M, Wannamethee G. Observer bias in blood pressure studies. J Hypertens. 1988;6:375-380.
24. Holzgreve H, Distler A, Michaelis J, Philipp T, Wellek S. Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of a long term double blind comparative trial. BMJ. 1989;229: 881-886.
25. Crout JR. Fixed combination prescription drugs: FDA policy. J Clin Pharmacol. 1974;14:249-254.
26. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
27. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional regimen along with various drug monotherapies. Arch Intern Med. 1991;151:1413-1423.
28. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251: 1006-1008.
29. Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occurring during rauwolfia therapy. JAMA. 1955;159:836-839.
30. Participating Veterans Administration Medical Centers. Low doses versus standard dose of reserpine. JAMA. 1982;248:2471-2477.
31. Goldstein G, Materson BJ, Cushman WC, Reda DJ, Preis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH, Khatri I, Schnaper H, Thomas JR, Henderson WG, Fye C. Treatment of hypertension in the elderly. II: cognitive and behavioral function - results of a Department of Veterans Affairs Cooperative Study. Hypertension. 1990;15:361-369.
32. Annual Report on Adverse Drug Events 1993. Basel. Switzerland: Drug Monitoring Center, Sandoz Ltd; 1993.
33. Bayotensin product leaflet. Bayropharm GmbH Internal data 1992. Wuppertal, Germany.
34. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-112.
35. Lederle FA, Applegate WB, Grimm RH. Reserpine and the medical market place. Arch Intern Med. 1993;153:705-706.
36. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacological management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.